Vaxcyte, Inc.
PCVX
$54.03
$0.040.07%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 2.63% | -0.69% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 26.09% | 13.16% | |||
| Operating Income | -26.09% | -13.16% | |||
| Income Before Tax | -30.07% | -15.82% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -30.07% | -15.82% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -30.07% | -15.82% | |||
| EBIT | -26.09% | -13.16% | |||
| EBITDA | -28.53% | -11.48% | |||
| EPS Basic | -27.20% | -15.62% | |||
| Normalized Basic EPS | -27.19% | -15.62% | |||
| EPS Diluted | -27.20% | -15.62% | |||
| Normalized Diluted EPS | -27.19% | -15.62% | |||
| Average Basic Shares Outstanding | 2.25% | 0.17% | |||
| Average Diluted Shares Outstanding | 2.25% | 0.17% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||